Pharma Focus Asia

FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis

The US Food and Drug Administration (FDA) grants Proteostasis Therapeutics' PTI-428, a Breakthrough therapy for the treatment of cystic fibrosis patients with two copies of the F508del genetic mutation who are receiving Orkambi® as background therapy.

PTI-428 is an investigational CFTR amplifier in the development for treating CF in patients who are homozygous for the F508del mutation in the CFTR gene.

It can be used as an add-on therapy to the approved CFTR modulators or as part of PTI’s proprietary triple combination regimen that includes PTI-808, a potentiator, and PTI-801, a corrector.

PTI-428 works early during CFTR biogenesis to increase levels of newly synthesized CFTR protein, suggesting potential therapeutic benefits in combination with CFTR correctors and potentiators.

It helps to treat CF patients based on the results from a recent Phase 2, randomised, placebo controlled study, in 24 CF subjects on background treatment with Orkambi® and who were treated with either 50 mg PTI-428 once daily or placebo for 28 consecutive days.

The study results showed that treatment with PTI-428 led to mean absolute improvement in percent predicted forced expiratory volume in 1 second (ppFEV1) of 5.2 percentage points from baseline through Day 28 compared to placebo (p<0>

The Breakthrough Therapy Designation for PTI-428 showcases the strength of the recent Phase 2 study results for amplifier, which is a novel and proprietary class of CFTR modulators.

PTI-428 offers the potential for improvement in pulmonary function for patients with cystic fibrosis.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024